LAC-B

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 23 Jul 2025 filing date already counts against anyone who files later.

Record

Serial number

79437745

Mark type

Word mark

Filed

23 Jul 2025

Published for opposition

18 Aug 2026

Attorney of record

Erica Halstead

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of cardiovascular disorders and metabolic disorders; pharmaceutical preparations for the treatment of glaucoma and ocular hypertension; pharmaceutical preparations for the treatment of corneal endothelial disorder; sanitary preparations for medical use; pharmaceutical preparations for the treatment of conditions and diseases of the circulatory system; pharmaceutical preparations for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; hand-sanitizing preparations; antimicrobials for dermatologic use; disinfectants for sanitary purposes; household disinfectants; pharmaceutical and biological preparations for the treatment of diseases of the central nervous system, peripheral nervous system, sensory organs, the circulatory system, respiratory system, and the digestive system; pharmaceutical substances for the treatment of dermatological diseases, allergies and urogenital and anal conditions; pharmaceutical preparations, namely, amino acid for medical or veterinary purposes; pharmaceutical preparations for the prevention and treatment of disorders of the metabolic system; topical and oral antibiotics; pharmaceutical preparations for use in chemotherapy; chemotherapeutic agents having antineoplastic activity; crude drugs, namely, medicinal herbs made of rootstock, bark, leaves, fruits, seeds, musk and bear's gall, used for the treatment of pain, cold, fever, anemia, and for diuretics and astringents; antibiotic preparations for human use; anti-inflammatory agents, namely, topical preparations in the form of gels and salves, adhesive skin patches, liquid formulations, cream and sprays, all for relieving pain; analgesics; dietary supplements for human beings; live biotherapeutic product in the nature of living cells for medical purposes; biological preparations for medical purposes, namely probiotic preparations

Owner

• KOWA COMPANY, LTD., JP
• KOWA COMPANY, LTD., JP

Prosecution history

• 18 Aug 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 18 Aug 2026 — PUBLISHED FOR OPPOSITION
• 13 Aug 2026 — NOTIFICATION PROCESSED BY IB
• 12 Aug 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 29 Jul 2026 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
• 29 Jul 2026 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
• 20 Jul 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 15 Jul 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 15 Jul 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 15 Jul 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 05 Mar 2026 — CORRECTION TRANSACTION RECEIVED FROM IB
• 19 Feb 2026 — REFUSAL PROCESSED BY IB
• 31 Jan 2026 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
• 31 Jan 2026 — REFUSAL PROCESSED BY MPU
• 03 Jan 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW